Vaccine News and Research

Latest Vaccine News and Research

Microbiologist receives contract from U.S. DOD to develop vaccine against tularemia

Microbiologist Karl Klose, a professor in the UTSA College of Sciences' Department of Biology and a member of the South Texas Center for Emerging Infectious Diseases, has received a contract from the U.S. Department of Defense (DOD) to conduct research that would bring scholars one step closer to developing a vaccine against tularemia.

14 Aug 2014

Research and planning to meet health needs of people living with HIV

As effective treatments for HIV become more widely available in low- and middle-income countries, there's an urgent need to assess and manage health risks in the growing number of people living with HIV.

14 Aug 2014

MicroVAX begins phase I clinical trial for proprietary cancer vaccine platform

MicroVAX, LLC, a biotech company located in Manassas, Virginia announced today the commencement of a phase I clinical trial for its unique and proprietary vaccine platform that allows under the provisions of an FDA IND entry of patients with cancers of the, breast, prostate, colon, ovary and lung, that have relapsed after initial salvage therapy.

13 Aug 2014

High-dose influenza vaccine 24% more effective in older adults

High-dose influenza vaccine is 24 percent more effective than the standard-dose vaccine in protecting persons ages 65 and over against influenza illness and its complications, according to a Vanderbilt-led study published today in the New England Journal of Medicine.

13 Aug 2014

Tarsa obtains $10 million senior credit facility to support NDA submission for Ostora tablet

Tarsa Therapeutics, Inc. today announced that it has secured a $10 million senior credit facility from Oxford Finance LLC and Square 1 Bank. The company intends to use the proceeds to support its plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration for its Ostora tablet for the treatment of postmenopausal osteoporosis, currently targeted for early 2015.

13 Aug 2014

Prevalence of bacterial meningitis drops in the United States

Advances in the prevention and treatment of an often fatal condition called bacterial meningitis appear to be paying dividends in the United States, report infectious disease experts at The University of Texas Health Science Center at Houston (UTHealth) in the journal The Lancet Infectious Diseases.

13 Aug 2014

Canadian government to donate experimental vaccine to combat Ebola virus

The Honourable Rona Ambrose, Minister of Health, today announced that the Government of Canada will donate doses of an experimental Ebola vaccine developed by the Public Health Agency of Canada to the World Health Organization (WHO) in its role as an international coordinating body in responding to the ongoing Ebola outbreak in West Africa.

13 Aug 2014

Lung-damaging bacterium turns body's antibody response in its favor

A lung-damaging bacterium turns the body's antibody response in its favor, according to a study published in The Journal of Experimental Medicine.

13 Aug 2014

Plan International outlines strategies to combat Ebola outbreak

The current Ebola outbreak, the most severe and complex in history, is now making its impact felt worldwide.

12 Aug 2014

Injecting vaccine-like compound into mice effective in protecting from malaria

A study led by Johns Hopkins Bloomberg School of Public Health researchers found that injecting a vaccine-like compound into mice was effective in protecting them from malaria.

12 Aug 2014

New approach to knocking out parasite's genes

Plasmodium falciparum, the parasite that causes malaria, has proven notoriously resistant to scientists' efforts to study its genetics.

12 Aug 2014

GW researcher awarded grant to develop a model system to study PN infection

According to a recent World Health Organization report of the leading causes of death worldwide, one-third of all deaths are due to infectious and parasitic diseases. There are currently no vaccines for parasitic nematode (PN), or worm infections in humans, and development of new drugs and vaccines will stall until researchers have a better understanding of PN biology.

11 Aug 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013.

11 Aug 2014

Alexza Pharmaceuticals announces availability of ADASUVE inhalation powder in Guatemala

Alexza Pharmaceuticals, Inc. today announced that ADASUVE inhalation powder, pre-dispensed (loxapine) is now available in Guatemala. This approval represents the first ADASUVE approval in Latin America for Ferrer and Alexza.

8 Aug 2014

New method of growing human cells may help develop tailor-made therapies for GI conditions

A method of growing human cells from tissue removed from a patient's gastrointestinal (GI) tract eventually may help scientists develop tailor-made therapies for inflammatory bowel disease and other GI conditions.

8 Aug 2014

Viewpoints: Why Emory accepted American Ebola cases; calls for terrified Americans to 'chill out'

Blame it on Richard Preston. "The Hot Zone," his 1994 nonfiction science thriller about the spread and devastation of the Ebola virus, pretty much set the standard for terrifying contagion scenarios. ...

8 Aug 2014

Many hospitals struggle to meet electronic health records deadline and face penalties

Many of the nation's hospitals struggled to meet a federally mandated electronic health records deadline, and as a result could collectively face millions of dollars in reduced Medicare payments this year, a University of Michigan study shows.

7 Aug 2014

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax™.

7 Aug 2014

Researchers plan to develop vaccine into a type of antibody serum therapy

By many estimates, an Ebola vaccine could be available in humans as early as next year. But will it be the right one? There are a number of vaccines in development and each is in a race to prove that it is most effective, safe and that it will protect the largest number of people.

7 Aug 2014

Small molecule may be able to convince damaged nerves to effectively rewire circuits

Frogs, dogs, whales, snails can all do it, but humans and primates can't. Regrow nerves after an injury, that is—while many animals have this ability, humans don't.

6 Aug 2014